Oric Pharmaceuticals, Inc. (ORIC) stock
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.86−0.64 (-7.53%)
Close on Nov 13, 2026Market cap $814.71MP/E –Yield –
Oric Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Oric Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $122.36M, up 3.4% year over year. For fiscal 2025 it was $109.82M, down 3.7% from the year before. The highest annual figure on record is $114.07M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.82M | -3.7% |
| FY2024 | Dec 31, 2024 | $114.07M | +33.9% |
| FY2023 | Dec 31, 2023 | $85.17M | +38.1% |
| FY2022 | Dec 31, 2022 | $61.68M | +8.5% |
| FY2021 | Dec 31, 2021 | $56.86M | +58.3% |
| FY2020 | Dec 31, 2020 | $35.92M | +57.2% |
| FY2019 | Dec 31, 2019 | $22.84M | +20.1% |
| FY2018 | Dec 31, 2018 | $19.03M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $36.30M | +18.8% |
| Q1 FY2026 | Mar 31, 2026 | $31.44M | +27.6% |
| Q4 FY2025 | Dec 31, 2025 | $25.86M | -19.1% |
| Q3 FY2025 | Sep 30, 2025 | $28.77M | -7.8% |
| Q2 FY2025 | Jun 30, 2025 | $30.55M | +5.6% |
| Q1 FY2025 | Mar 31, 2025 | $24.64M | +12.2% |
| Q4 FY2024 | Dec 31, 2024 | $31.97M | +30.6% |
| Q3 FY2024 | Sep 30, 2024 | $31.20M | +39.4% |
| Q2 FY2024 | Jun 30, 2024 | $28.94M | +54.0% |
| Q1 FY2024 | Mar 31, 2024 | $21.96M | +12.5% |
| Q4 FY2023 | Dec 31, 2023 | $24.48M | +50.2% |
| Q3 FY2023 | Sep 30, 2023 | $22.39M | +52.1% |
| Q2 FY2023 | Jun 30, 2023 | $18.79M | +35.8% |
| Q1 FY2023 | Mar 31, 2023 | $19.52M | +16.0% |
| Q4 FY2022 | Dec 31, 2022 | $16.30M | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $14.72M | +14.1% |
| Q2 FY2022 | Jun 30, 2022 | $13.83M | -10.8% |
| Q1 FY2022 | Mar 31, 2022 | $16.83M | +43.9% |
| Q4 FY2021 | Dec 31, 2021 | $16.75M | +38.2% |
| Q3 FY2021 | Sep 30, 2021 | $12.90M | +46.1% |
| Q2 FY2021 | Jun 30, 2021 | $15.52M | +100.9% |
| Q1 FY2021 | Mar 31, 2021 | $11.70M | +61.2% |
| Q4 FY2020 | Dec 31, 2020 | $12.11M | +74.0% |
| Q3 FY2020 | Sep 30, 2020 | $8.83M | +56.8% |
| Q2 FY2020 | Jun 30, 2020 | $7.72M | +53.2% |
| Q1 FY2020 | Mar 31, 2020 | $7.25M | +39.2% |
| Q4 FY2019 | Dec 31, 2019 | $6.96M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.63M | – |
| Q2 FY2019 | Jun 30, 2019 | $5.04M | – |
| Q1 FY2019 | Mar 31, 2019 | $5.21M | – |
See a number that looks wrong?